ARTS-021 is under clinical development by Avenzo Therapeutics and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ARTS-021’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ARTS-021 overview

ARTS-021 is under development for the treatment of metastatic solid tumor, HR positive HER2 negative breast cancer, epithelial ovarian cancer. It acts by targeting cyclin dependent kinase 2 (CDK2). It is administered through oral route in the form of tablet. The drug candidate acts by targeting cyclin dependent kinase 2 (CDK2). 

 It was under development for the treatment of triple negative breast cancer, endometrial cancer, small-cell lung cancer, gastroesophageal cancer and urothelial cancer.

Avenzo Therapeutics overview

Avenzo Therapeutics (Avenzo) is a clinical-stage biotechnology company. It develops next-generation oncology therapies that target cell cycle control to prevent the aberrant cell proliferation that drives many cancers. The company is developing its lead product candidate AVZO-021, a novel and highly potent inhibitor of cyclin-dependent kinase 2 (CDK-2), in the early-stage clinical development phase for the treatment of solid tumors. It works along with Allorion Therapeutics for product development. The company was funded by OrbiMed Healthcare Fund Management, Foresite Capital, SR One, Surveyor, and Lilly Asia Ventures. Avenzo is headquartered in San Diego, California, the US.

For a complete picture of ARTS-021’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.